Search Result

Results for "

PPAR-γ Agonists

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PPAR (147) Akt (1) Amyloid-β (2) Angiotensin Receptor (3) Antibiotic (4) Apoptosis (12) Autophagy (11) Bacterial (8) Biochemical Assay Reagents (1) Bombesin Receptor (1) Calcium Channel (1) Cannabinoid Receptor (1) COX (1) Cytochrome P450 (2) EGFR (1) Endogenous Metabolite (10) ERK (1) Estrogen Receptor/ERR (1) Ferroptosis (16) Free Fatty Acid Receptor (3) Fungal (2) Glucocorticoid Receptor (1) Glucosidase (3) HIF/HIF Prolyl-Hydroxylase (3) Isotope-Labeled Compounds (10) Keap1-Nrf2 (2) Leukotriene Receptor (1) LXR (2) NF-κB (9) Nuclear Hormone Receptor 4A/NR4A (1) PAK (7) PARP (1) Phosphatase (1) PI3K (1) Prostaglandin Receptor (2) RAR/RXR (4) TRP Channel (6)
By Research Areas:	Cancer (56) Cardiovascular Disease (21) Endocrinology (5) Infection (4) Inflammation/Immunology (40) Metabolic Disease (108) Neurological Disease (21)

By Targets:

PPAR (147)

Akt (1)

Amyloid-β (2)

Angiotensin Receptor (3)

Antibiotic (4)

Apoptosis (12)

Autophagy (11)

Bacterial (8)

Biochemical Assay Reagents (1)

Bombesin Receptor (1)

Calcium Channel (1)

Cannabinoid Receptor (1)

COX (1)

Cytochrome P450 (2)

EGFR (1)

Endogenous Metabolite (10)

ERK (1)

Estrogen Receptor/ERR (1)

Ferroptosis (16)

Free Fatty Acid Receptor (3)

Fungal (2)

Glucocorticoid Receptor (1)

Glucosidase (3)

HIF/HIF Prolyl-Hydroxylase (3)

Isotope-Labeled Compounds (10)

Keap1-Nrf2 (2)

Leukotriene Receptor (1)

LXR (2)

NF-κB (9)

Nuclear Hormone Receptor 4A/NR4A (1)

PAK (7)

PARP (1)

Phosphatase (1)

PI3K (1)

Prostaglandin Receptor (2)

RAR/RXR (4)

TRP Channel (6)

By Research Areas:

Cancer (56)

Cardiovascular Disease (21)

Endocrinology (5)

Infection (4)

Inflammation/Immunology (40)

Metabolic Disease (108)

Neurological Disease (21)

164

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: PPAR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15655

GW1929 5+ Cited Publications	PPAR	Neurological Disease Metabolic Disease
GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human *PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ* and murine *PPAR-γ*, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .

HY-N0246

Saikosaponin A 1 Publications Verification	LXR Bacterial	Inflammation/Immunology Cancer
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-120160

Darglitazone CP-86325	PPAR	Neurological Disease Metabolic Disease
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active *PPAR-γ* agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-146480

PPARγ agonist 5	PPAR	Cancer
PPARγ agonist 5 (Compound 1) is a potent and selective agonist of *PPARγ. PPARγ* agonist 5 has the potential for the research of cancer diseases .

HY-110022

GW1929 hydrochloride	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human *PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ* and murine *PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis* and shows anti-inflammatory potential .

HY-113473

10-Nitrolinoleic acid	PPAR	Metabolic Disease Inflammation/Immunology Cancer
10-Nitrolinoleic acid is a potent *peroxisome proliferator-activated receptor γ (PPARγ)* agonist. 10-Nitrolinoleic acid competes with [ ³H]Rosiglitazone for binding to PPAR-γ, with an IC₅₀ of 0.22 μM .**

HY-14831

Arhalofenate MBX 102; JNJ 39659100	PPAR	Metabolic Disease
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor *(PPAR)-γ*, used for the treatment of type 2 diabetes.

HY-N0246R

Saikosaponin A (Standard)	LXR Bacterial	Metabolic Disease Inflammation/Immunology
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-120160A

Darglitazone Sodium CP 86325 Sodium	PPAR	Neurological Disease Metabolic Disease
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective *PPAR-γ* (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-106181A

Rivoglitazone hydrochloride R-106056 hydrochloride	PPAR	Metabolic Disease
Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating *PPARγ* to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes .

HY-146482

PPARγ agonist 6	PPAR	Cancer
PPARγ agonist 6 (Compound 12) is a potent and selective agonist of *PPARγ. PPARγ* agonist 6 has the potential for the research of cancer diseases .

HY-146438

PPARγ agonist 3	PPAR	Cancer
PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of *PPARγ. PPARγ* agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib .

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of *PPARγ. PPARγ* agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-146439

PPARγ agonist 4	PPAR	Cancer
PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of *PPARγ. PPARγ* agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib .

HY-147511

PPARγ agonist 7	PPAR	Others
PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of *PPARγ. PPARγ* agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC₅₀, 4.34 μM) .

HY-153982

PPARγ agonist 8	PPAR	Metabolic Disease
PPARγ agonist 8 is an agonist of *PPARγ. PPARγ* agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC₅₀ of 0.2 μM .

HY-146731

PPARγ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
PPARγ agonist 1 (compound 15) is a potent agonist of *PPARγ. PPARγ* agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .

HY-162320

PPARγ agonist 12	PPAR	Metabolic Disease
PPARγ agonist 12 (compound 9i) is a potent and selective *PPARγ* agonist with EC₅₀s of 3.98 and 15.42 μM against *PPARγ* and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .

HY-N6869

Dehydroabietic acid	Antibiotic PPAR Bacterial Fungal	Infection Metabolic Disease Inflammation/Immunology Cancer
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-146742

PPARγ agonist 2	PPAR	Metabolic Disease
PPARγ agonist 2 is a potent *PPARγ* partial agonist and can be used for metabolic disease research .

HY-116468

PPARγ agonist 11	PPAR	Metabolic Disease
PPARγ agonist 11 (compound 20) is a selective agonist of *PPARγ* (EC₅₀: 0.1 μM) .

HY-B0205

Candesartan 5 Publications Verification CV 11974	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and *PPAR-γ* agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-16086

Balaglitazone 1 Publications Verification DRF 2593; NN 2344	PPAR	Metabolic Disease
Balaglitazone is a selective partial *PPARγ* agonist with an EC₅₀ of 1.351 μM for human *PPARγ*.

HY-163294

PPARγ agonist 10	PPAR	Metabolic Disease
PPARγ agonist 10 (compound 33g) is a *PPARγ* agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .

HY-148351

BAY-0069	PPAR	Cancer
BAY-0069 is a potent and selective *PPARγ* inverse agonist with an IC₅₀ value of 6.3 nM and 24 nM for human PPARγ and mouse PPARγ. BAY-0069 can be used to research cancer .

HY-14792

Inolitazone Efatutazone; CS-7017; RS5444	PPAR	Cancer
Inolitazone a novel high-affinity *PPARγ* agonist that is dependent upon PPARγ for its biological activity with IC₅₀ of 0.8 nM for growth inhibition.

HY-14601

Pioglitazone hydrochloride 25+ Cited Publications U 72107A; AD 4833	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone hydrochloride is a potent and selective *PPARγ* agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-N6869R

Dehydroabietic acid (Standard)	Antibiotic PPAR Bacterial Fungal	Infection Metabolic Disease Inflammation/Immunology Cancer
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-14792B

Inolitazone dihydrochloride 4 Publications Verification Efatutazone dihydrochloride; CS-7017 dihydrochloride; RS5444 dihydrochloride	PPAR	Cancer
Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a novel high-affinity *PPARγ* agonist that is dependent upon PPARγ for its biological activity with IC₅₀ of 0.8 nM for growth inhibition.

HY-150308

SR10221	PPAR	Cancer
SR10221, a noncovalent inverse agonist of *PPARγ, represses downstream PPARγ* target genes leading to growth inhibition in bladder cancer cell lines .

HY-154985

DSO-5a	PPAR Bombesin Receptor ERK	Metabolic Disease
DSO-5a is a potent, selective, orally active BB₃ agonist. DSO-5a is a representative DMAKO-00 derivative compound. DSO-5a upregulates *ppar-γ* activity through BB₃ and activates ERK1/2 phosphorylation. DSO-5a can be used in diabetes-related research .

HY-B0205R

Candesartan (Standard) CV 11974 (Standard)	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and *PPAR-γ* agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-50935S

Troglitazone-d4 CS-045-d₄	Isotope-Labeled Compounds PPAR Autophagy Apoptosis Ferroptosis	Cancer
Troglitazone-d₄ is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

HY-13956S

Pioglitazone-d4 U 72107-d₄	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone-d₄ is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1].

HY-116521

SR2595	PPAR	Metabolic Disease
SR2595 is an inverse agonist of *PPARγ* with an IC₅₀ of 30 nM .

HY-B0287

Clofibrate 2 Publications Verification	PPAR	Metabolic Disease
Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ*, respectively.

HY-100428

Netoglitazone MCC-555; Isaglitazone	PPAR	Metabolic Disease
Netoglitazone is a dual agonist of PPARα and PPARγ with antihyperglycemic activity .

HY-13956

Pioglitazone 25+ Cited Publications U 72107	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) is an orally active and selective *PPARγ* (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-13956B

Pioglitazone potassium U 72107 potassium	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) potassium is an orally active and selective *PPARγ* (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research .

HY-50935

Troglitazone 20+ Cited Publications CS-045	PPAR Autophagy Apoptosis Ferroptosis	Metabolic Disease Cancer
Troglitazone is an orally active *PPARγ* agonist, with EC₅₀s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.

HY-106181

Rivoglitazone R-106056	PPAR	Metabolic Disease
Rivoglitazone is a thiazolidinedione-derivative *PPARγ* agonist for the research of type 2 diabetes mellitus.

HY-N2025

Oroxin A	PPAR Glucosidase	Metabolic Disease
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial *PPARγ* agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-117727

Leriglitazone MIN-102; Hydroxypioglitazone	PPAR	Metabolic Disease
Leriglitazone (MIN-102; Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone PioOH is a *PPARγ* agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K_i of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC₅₀ of 680 nM .

HY-117727A

Leriglitazone hydrochloride MIN-102 hydrochloride; Hydroxypioglitazone hydrochloride	PPAR	Metabolic Disease
Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone hydrochloride PioOH is a *PPARγ* agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K_i of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC₅₀ of 680 nM .

HY-110118

Edaglitazone	PPAR	Metabolic Disease
Edaglitazone is a potent, selective and orally active *PPARγ* agonist, with EC₅₀s of 35.6 nM and 1053 nM for PPARα and *PPARγ*, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .

HY-108572

S26948	PPAR	Cardiovascular Disease Metabolic Disease
S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC₅₀=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ .

HY-14601R

Pioglitazone hydrochloride (Standard) U 72107A (Standard); AD 4833 (Standard)	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (hydrochloride) (Standard) is the analytical standard of Pioglitazone (hydrochloride). This product is intended for research and analytical applications. Pioglitazone hydrochloride is a potent and selective *PPARγ* agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-13956S1

Pioglitazone-d4 (alkyl)	Isotope-Labeled Compounds PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone-d₄ (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1][2].

HY-111254

GQ-16	PPAR	Metabolic Disease
GQ-16 is a moderate affinity ligand for the ligand-binding domain (LBD) of *PPARγ, exhibiting a K_i* of 160 nM. GQ-16 is an effective inhibitor of Cdk5-mediated phosphorylation of PPARγ. GQ-16 is a partial agonist of PPARγ with reduced adipogenic actions. GQ-16 promotes insulin Sensitization without weight gain .

HY-N9333

Wistin	PPAR	Metabolic Disease Cancer
Wistin, isolated from Caragana sinica roots, is a PPARα and *PPARγ* agonist .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0246

Saikosaponin A 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Umbelliferae Plants Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray Cancer	LXR Bacterial
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-N6869

Dehydroabietic acid	Infection Structural Classification Microorganisms other families Classification of Application Fields Anti-aging Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N2025

Oroxin A	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Metabolic Disease Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz Disease Research Fields	PPAR Glucosidase
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial *PPARγ* agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-N0234

Bavachinin 3 Publications Verification 7-O-Methylbavachin; Bavachinin A	Structural Classification Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N0246R

Saikosaponin A (Standard)	Triterpenes Structural Classification Terpenoids Source classification Umbelliferae Plants Carphephorus corymbosus (Nutt.) Torr. & A.Gray	LXR Bacterial
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-N6869R

Dehydroabietic acid (Standard)	Structural Classification Microorganisms other families Terpenoids Source classification Diterpenoids Plants	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N9333

Wistin	Flavonoids other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields Isoflavones	PPAR
Wistin, isolated from Caragana sinica roots, is a PPARα and *PPARγ* agonist .

HY-13956R

Pioglitazone (Standard)	Human Gut Microbiota Metabolites Source classification Endogenous metabolite	PPAR Ferroptosis
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective *PPARγ* (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-N2025R

Oroxin A (Standard)	Structural Classification Flavonoids Flavones Source classification Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz	PPAR Glucosidase
Oroxin A (Standard) is the analytical standard of Oroxin A. This product is intended for research and analytical applications. Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-N0234R

Bavachinin (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-U00450

4-O-Methyl honokiol	Classification of Application Fields Source classification Lignans Plants Monophenols other families Magnolia officinalis. Rehd. et Wils. Magnoliaceae Phenols Phenylpropanoids Inflammation/Immunology Disease Research Fields Cancer	PPAR NF-κB
4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a *PPARγ* agonist, and inhibtis NF-κB activity, used for cancer and inflammation research.

HY-N7624

Methyl oleanonate 3-Oxoolean-12-en-28-oic acid methyl ester	Triterpenes Pistacia lentiscus var. Chia other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Cancer Anacardiaceae	PPAR
Methyl oleanonate is a natural triterpene *PPARγ* agonist isolated from the species of Pistacia lentiscus var. Chia . Methyl oleanonate is a modified oleanolic acid derivative with anti-cancer effects .

HY-N0163

Magnolol 4 Publications Verification	Cardiovascular Disease Structural Classification Neurological Disease Classification of Application Fields Source classification Lignans Plants Magnolia officinalis. Rehd. et Wils. Magnoliaceae Phenols Polyphenols Phenylpropanoids Inflammation/Immunology Disease Research Fields	RAR/RXR PPAR Autophagy Bacterial
Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and *PPARγ, with EC₅₀* values of 10.4 µM and 17.7 µM, respectively.

HY-113631

Amorfrutin B	Structural Classification Monophenols Leguminosae Source classification Phenols Amorpha fruticosaL. Plants	PPAR
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with K_i values of 19 nM and EC₅₀ values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .

HY-15027

5-Aminosalicylic Acid Maximum Cited Publications 16 Publications Verification Mesalamine; 5-ASA; Mesalazine	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields Cancer	PPAR PAK NF-κB Endogenous Metabolite
5-Aminosalicylic acid (Mesalamine) acts as a specific *PPARγ* agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-N7687

Caulophyllogenin	Triterpenes Classification of Application Fields Leguminosae Terpenoids Source classification Acacia catechu (Linn. f.) Willd. Plants Disease Research Fields Inflammation/Immunology	PPAR
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial *PPARγ* agonist, with an EC₅₀ of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation .

HY-111616

GSK1820795A	Cardiovascular Disease Classification of Application Fields Disease Research Fields	PPAR Angiotensin Receptor
GSK1820795A, as a telmisartan analog, is a selective hGPR132a antagonist. GSK1820795A blocks activation of yeast cells expressing hGPR132a by N-acylamides . GSK1820795A is also a angiotensin II antagonists and partial *PPARγ* agonists (compound 38) .

HY-N6642

Ankaflavin	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields	PPAR Apoptosis
Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active *PPARγ* agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects .

HY-N0163R

Magnolol (Standard)	Structural Classification Magnolia officinalis. Rehd. et Wils. Magnoliaceae Source classification Lignans Phenols Polyphenols Phenylpropanoids Plants	RAR/RXR PPAR Autophagy Bacterial
Magnolol (Standard) is the analytical standard of Magnolol. This product is intended for research and analytical applications. Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 μM and 17.7 μM, respectively.

HY-N6641

Monascin	Structural Classification Natural Products Microorganisms other families Classification of Application Fields Source classification Pigments Plants Inflammation/Immunology Disease Research Fields Food Research	Keap1-Nrf2 PPAR
Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and *PPARγ* agonist .

HY-15027R

5-Aminosalicylic Acid (Standard)	Structural Classification Monophenols Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite	PPAR PAK NF-κB Endogenous Metabolite
5-Aminosalicylic Acid (Standard) is the analytical standard of 5-Aminosalicylic Acid. This product is intended for research and analytical applications. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-N10361

Drupanin	Monophenols Animals Classification of Application Fields Source classification Phenols Disease Research Fields Cancer	RAR/RXR PPAR
Drupanin is an orally active selective AKR1C3 enzyme inhibitor and an RXRα agonist with an EC₅₀ value of 4.8 μM, which is isolated from green propolis. Drupanin also activates *PPARγ* moderately. Drupanin induces adipogenesis and elevates aP2 mRNA levels in 3T3-L1 fibroblasts Drupanin has the potential for the research of breast and prostate cancers .

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 1 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective *PPARγ* (EC₅₀ of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

HY-108568R

15-Deoxy-Δ-12,14-prostaglandin J2 (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (Standard) is the analytical standard of 15-Deoxy-Δ-12,14-prostaglandin J2. This product is intended for research and analytical applications. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

Cat. No.	Product Name	Chemical Structure

HY-13956S

Pioglitazone-d4
Pioglitazone-d₄ is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1].

HY-13956S1

Pioglitazone-d4 (alkyl)
Pioglitazone-d₄ (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1][2].

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-15027S

5-Aminosalicylic Acid-d3 hydrochloride
5-Aminosalicylic Acid-d₃ (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.

HY-50935S

Troglitazone-d4
Troglitazone-d₄ is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

HY-B0287S

Clofibrate-d4
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

HY-117727S

Leriglitazone-d4

Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

HY-17386S

Rosiglitazone-d3
Rosiglitazone-d₃ is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3[1][2][3][4].

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-19937S1

Saroglitazar-d4
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-15027S1

5-Aminosalicylic acid-d3
5-Aminosalicylic acid-d₃ is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[1][2][3][4].

HY-15027S2

5-Aminosalicylic acid-13C6
5-Aminosalicylic acid- ¹³C₆ is the ¹³C labeled 5-Aminosalicylic Acid[1]. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[2][3][4].

HY-17386S1

Rosiglitazone-d4
Rosiglitazone-d₄ is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective *PPARγ* agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-15027S3

5-Aminosalicylic acid-d3 disodium
5-Aminosalicylic acid-d₃ disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific *PPARγ* agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-143704S

5-Aminosalicylic acid-13C6 hydrochloride
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4

15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks